A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer

Feasibility Study of Randomizing Patients to Telemedicine Shared Medical Appointments Versus Telemedicine Single Visits for Men With Prostate Cancer on Active Surveillance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05416996

Enrollment

Registered

2022-06-14

Start date

2022-06-05

Completion date

2027-06-01

Last updated

2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Telemedicine, Shared Medical Appointments, Individual Telemedicine Visits, 22-184

Brief summary

The purpose of this study is to see if a telemedicine group doctor's appointment is a practical (feasible) and acceptable method for following people with prostate cancer being managed with active surveillance when compared with the usual approach of individual telemedicine visits, which involve the participant visiting a doctor on their own. The researchers will compare the telemedicine group and individual visits by measuring on participant satisfaction and quality of life in each type of visit. Telemedicine is the use of secure video technology on a desktop computer, laptop, smartphone, or tablet to provide and receive healthcare from a distance.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* A scheduled appointment for a subsequent Active Surveillance (AS) follow-up visit for management of localized prostate cancer * Biopsy Gleason score 3+3=6 (Grade Group 1) or biopsy Gleason score 3+4=7 (Grade Group 2) * Clinical T stage ≤T2B * Access to a device with Zoom * Ability to speak and understand English

Exclusion criteria

* Plan to undergo a prostate biopsy at this follow-up visit

Design outcomes

Primary

Measure	Time frame	Description
accrual number	1 year	—
patient satisfaction	1 week	using MSK Engage portal survey

Secondary

Measure	Time frame	Description
adherence to active surveillance	6 months	the number who drop out of AS in the absence of disease progression

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBehfar Ehdaie, MD, MPH

Memorial Sloan Kettering Cancer Center

Outcome results